Department of Defense Pharmacy Uniform Formulary Blanket Purchase Agreement/Uniform Formulary Additional Discount Program
Closed Solicitation Posted
- Solicitation number
- HT9402-25-Q-9101
- Agency
-
Defense Health Agency
Department of Defense
- Responses due
- Set-aside
- No set-aside
Opportunity facts
- NAICS code
- 325412 Pharmaceutical Preparation Manufacturing
- PSC
- 6505 Drugs And Biologicals
- Place of performance
- San Antonio, Texas 78230, United States
- Points of contact
Notice details come from SAM.gov. Updated .
About this opportunity
The Department of Defense (DoD) is seeking quotes from pharmaceutical manufacturers for Uniform Formulary Blanket Purchase Agreements (UF BPA) and Uniform Formulary Additional Discount Program Agreements (UF ADP) for pharmaceutical agents in the Narcotic Analgesics and Combinations, and Sleep Disorders: Wakefulness Promoting Agents drug classes. This solicitation is being issued by the Defense Health Agency prior to the DoD Pharmacy and Therapeutics (P&T) Committee's February 2025 meeting, where they will evaluate the relative clinical and cost effectiveness of the agents for potential placement on the DoD Uniform Formulary. Manufacturers must submit quotes by December 30, 2024 and provide responses to clinical questions by November 25, 2024. A pre-quotation teleconference is scheduled for November 12, 2024.
The solicitation does not have a set-aside designation. The DoD may award UF BPA and UF ADP agreements based on the P&T Committee's formulary decisions. The place of performance is San Antonio, TX. No potential incumbents or current contractors are named, and the solicitation does not specify award values or budget ranges. However, the DoD is seeking to establish an effective, efficient, integrated pharmacy benefits program for the Military Health System through this procurement.
Notice text
2 versions
Update #2 · Latest ·
The Department of Defense (DoD) is required by law (10 U.S.C. § 1074g) to establish an effective, efficient, integrated pharmacy benefits program for the Military Health System (MHS) which includes the purchase pharmaceutical agents. The law and implementing regulation (32 CFR Section 199.21) describe the process by which the DoD Pharmacy and Therapeutics (P&T) Committee will consider the relative clinical effectiveness and relative cost effectiveness of pharmaceutical agents in a therapeutic class in recommending the selection of agents for the DoD Uniform Formulary (UF) and, for cost sharing purposes, the classification of a pharmaceutical agent as generic, formulary, Basic Core Formulary (BCF), Extended Core Formulary (ECF), or non-formulary (NF). Prior to the scheduled P&T Committee meeting, a Request for Quotation (RFQ) for pharmaceutical agents within Drug Classes identified for placement on the UF has been issued to obtain quotes from industry. The Defense Health Agency may award Uniform Formulary Blanket Purchase Agreements (UF BPA) and the Uniform Formulary Additional Discount Program Agreements (UF ADP) based on the UF decision. This process is described in the attached RFQ.
P&T COMMITTEE MEETING: February 2025: The following drug classes/subclass will be reviewed:
a. NARCOTIC ANALGESICS AND COMBINATIONS: BUPRENORPHRINE AND COMBINATIONS
Belbuca
Zubsolv
b. SLEEP DISORDERS: WAKEFULNESS PROMOTING AGENTS
Lumryz
Sodium Oxybate
Sunosi
Wakix
Xyrem
Xywav
The RFQ, including UF BPA and UF ADP appendices are attached here in. The instructions, important deadlines, and points of contact are in document, RFQ HT9402-25-Q-9101.
Pre-quotation teleconference is on November 12, 2024, details are stated in Part 2.5. Pre-quotation teleconference, contact RFQ Point of Contact (POC) for agenda and dial-in information. Responses to the clinical questions in Part 3.4 shall be submitted via e-mail to the RFQ POC (stated in Part 2.3), no later than the date stated in Part 2.4.
Update #1 ·
The Department of Defense (DoD) is required by law (10 U.S.C. § 1074g) to establish an effective, efficient, integrated pharmacy benefits program for the Military Health System (MHS) which includes the purchase pharmaceutical agents. The law and implementing regulation (32 CFR Section 199.21) describe the process by which the DoD Pharmacy and Therapeutics (P&T) Committee will consider the relative clinical effectiveness and relative cost effectiveness of pharmaceutical agents in a therapeutic class in recommending the selection of agents for the DoD Uniform Formulary (UF) and, for cost sharing purposes, the classification of a pharmaceutical agent as generic, formulary, Basic Core Formulary (BCF), Extended Core Formulary (ECF), or non-formulary (NF). Prior to the scheduled P&T Committee meeting, a Request for Quotation (RFQ) for pharmaceutical agents within Drug Classes identified for placement on the UF has been issued to obtain quotes from industry. The Defense Health Agency may award Uniform Formulary Blanket Purchase Agreements (UF BPA) and the Uniform Formulary Additional Discount Program Agreements (UF ADP) based on the UF decision. This process is described in the attached RFQ.
P&T COMMITTEE MEETING: February 2025: The following drug classes/subclass will be reviewed:
a. NARCOTIC ANALGESICS AND COMBINATIONS: BUPRENORPHRINE AND COMBINATIONS
Belbuca
Zubsolv
b. SLEEP DISORDERS: WAKEFULNESS PROMOTING AGENTS
Lumryz
Sunosi
Wakix
Xyrem
Xywav
The RFQ, including UF BPA and UF ADP appendices are attached here in. The instructions, important deadlines, and points of contact are in document, RFQ HT9402-25-Q-9101.
Pre-quotation teleconference is on November 12, 2024, details are stated in Part 2.5. Pre-quotation teleconference, contact RFQ Point of Contact (POC) for agenda and dial-in information. Responses to the clinical questions in Part 3.4 shall be submitted via e-mail to the RFQ POC (stated in Part 2.3), no later than the date stated in Part 2.4.
Files
| File | Type | Posted |
|---|---|---|
| Amendment 0001.pdf | ||
| A0001 RFQ HT9402-25-Q-9101 CR.pdf | ||
| A0001 NDC Price List - Narcotics Analgesics and Combinations - Buprenorphine and Combinations.xlsx | XLSX spreadsheet | |
| NDC Price List - Sleep Disorders - Wakefulness Promoting Agents.xlsx | XLSX spreadsheet | |
| A0001 NDC Price List - Sleep Disorders - Wakefulness Promoting Agents.xlsx | XLSX spreadsheet | |
| NDC Price List - Narcotics Analgesics and Combinations - Buprenorphine and Combinations.xlsx | XLSX spreadsheet | |
| RFQ HT9402-25-Q-9101 CR.pdf | ||
| NDC Price List - Sleep Disorders - Wakefulness Promoting Agents.xlsx | XLSX spreadsheet | |
| NDC Price List - Narcotics Analgesics and Combinations - Buprenorphine and Combinations.xlsx | XLSX spreadsheet | |
| Price Appendix FAQ CR.pdf | ||
| Feb 2025 PT Meeting Reporting.xlsx | XLSX spreadsheet |
Show all 11
On GovTribe
Work this opportunity
- Track it in your pipeline
- Find teaming partners
- Similar opportunities
- Ask GovTribe AI about this opportunity